We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

DNT Signs Collaboration Agreement with NCL

DNT Signs Collaboration Agreement with NCL

DNT Signs Collaboration Agreement with NCL

DNT Signs Collaboration Agreement with NCL

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DNT Signs Collaboration Agreement with NCL"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Dendritic Nanotechnologies Inc. (DNT) has announced that it has entered into one of the first characterization collaborations with the Nanotechnology Characterization Laboratory (NCL), an organization established by the National Cancer Institute to foster collaboration between the government and the private sector.

The agreement with NCL will focus on the characterization by NCL of DNT's STARBURST™ dendrimers as macromolecular dendrimer-based MRI contrast agents for sensitive, non-invasive cardiovascular diagnostics.

DNT's STARBURST and Priostar™ dendrimers are "smart" biopharmaceutical nanotechnology platforms that can be used to deliver precise quantities of a drug or contrast agent to a specific location within the human body.

DNT's dendrimers will be subjected to an assay cascade consisting of physical characterization, in vitro studies, and in vivo ADME/Tox protocols to determine their absorption, distribution, metabolism, excretion, and toxicity.

DNT's proprietary dendrimer platform also serves as a targeted diagnostic and therapeutic delivery system for a wide variety of drugs to cancer cells and other diseases. 

The intent of these studies is to generate data in support of an investigative new drug (IND) filing with the U.S. Food and Drug Agency (FDA). It is estimated that the NCL's characterization efforts will take approximately 12-15 months.

“Development of dendrimer-based MRI contrast agents for sensitive, non- invasive intravascular agents is highly desired in the medical world,” said Robert Berry, DNT's chief executive officer.

“DNT's STARBURST dendrimers have demonstrated intravascular properties that increase sensitivity and image clarity with potentially lower dosage compared to currently available general- use contrast agents.”

“DNT's smart nanostructures feature precise and predictable physical properties that make them especially useful in commercial applications requiring novel properties with nanometer precision.”

The collaboration agreement with DNT is one of the first characterization agreements entered into by the NCL and will be used to perform a preclinical assessment of DNT's intravascular dendrimer-based MRI contrast agents.